{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "A",
          "alt": "P",
          "position": "30"
        },
        "variant_string_id": "SNCA A30P"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Failure of the proteosome to degrade misfolded protein is implicated in the accumulation of a-synuclein in Parkinson's disease (PD).",
          "judgment": "Yes",
          "reasoning": "The paper states that the accumulation of misfolded a-synuclein, due to proteasomal degradation failure, is involved in PD."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "HO-1 over-expression triggers proteosomal degradation of proteins and prevents intracellular accumulation of protein aggregates and inclusions. Resistance to HO-1 induced proteosomal degradation may render the familial PD-associated A30P mutation prone to toxic intracellular aggregation.",
          "judgment": "Yes",
          "reasoning": "The assay measures protein degradation by the proteosome, which directly relates to the defined disease mechanism of misfolded a-synuclein accumulation.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Actin was used as a control. Multiple replicates were used.",
          "judgment": "Yes",
          "reasoning": "The paper used both a normal control (Actin) and states that multiple replicates were performed for the experiments.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "HO-1 also significantly reduced aggregation of a-synuclein (WT) but not that of A30P.",
          "judgment": "Yes",
          "reasoning": "The paper tested the wild-type variant alongside the A30P variant.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "The data were presented as mean ± SE. Statistical analyses were performed by one-way ANOVA followed by Newman-Keuls post hoc comparisons to assess significant main effects within groups. Statistical significance was set at p < 0.05.",
          "judgment": "No",
          "reasoning": "While statistical tests were conducted, the paper does not calculate or provide enough data to calculate an OddsPath value.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "Unknown",
          "judgment": "N/A",
          "reasoning": "It is not clear how many variant controls were used across the study.",
          "next_step_or_outcome": "Max PS3_supporting / Max BS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The A30P mutation exhibits resistance to HO-1-induced proteosomal degradation. While statistically significant, there is no OddsPath calculation available and the number of benign/pathogenic variant controls used in the broader study is unknown, thus the pathogenic strength assigned is supporting."
    },
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "A",
          "alt": "T",
          "position": "53"
        },
        "variant_string_id": "SNCA A53T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Failure of the proteosome to degrade misfolded protein is implicated in the accumulation of a-synuclein in Parkinson's disease (PD).",
          "judgment": "Yes",
          "reasoning": "The paper states that the accumulation of misfolded a-synuclein, due to proteasomal degradation failure, is involved in PD."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "HO-1 over-expression triggers proteosomal degradation of proteins and prevents intracellular accumulation of protein aggregates and inclusions. Resistance to HO-1 induced proteosomal degradation may render the familial PD-associated A30P mutation prone to toxic intracellular aggregation.",
          "judgment": "Yes",
          "reasoning": "The assay measures protein degradation by the proteosome, which directly relates to the defined disease mechanism of misfolded a-synuclein accumulation.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Actin was used as a control. Multiple replicates were used.",
          "judgment": "Yes",
          "reasoning": "The paper used both a normal control (Actin) and states that multiple replicates were performed for the experiments.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The paper tested the wild-type variant alongside the A53T variant.",
          "judgment": "Yes",
          "reasoning": "The paper tested the wild-type variant alongside the A53T variant.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "The data were presented as mean ± SE. Statistical analyses were performed by one-way ANOVA followed by Newman-Keuls post hoc comparisons to assess significant main effects within groups. Statistical significance was set at p < 0.05.",
          "judgment": "No",
          "reasoning": "While statistical tests were conducted, the paper does not calculate or provide enough data to calculate an OddsPath value.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "Unknown",
          "judgment": "N/A",
          "reasoning": "It is not clear how many variant controls were used across the study.",
          "next_step_or_outcome": "Max PS3_supporting / Max BS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "In contrast to the A30P mutation, the A53T mutation did not significantly affect a-synuclein degradation by the proteasome in HO-1 over-expressing cells. While statistically significant, there is no OddsPath calculation available and the number of benign/pathogenic variant controls used in the broader study is unknown, thus the pathogenic strength assigned is supporting."
    }
  ]
}
